为解决骨肉瘤治疗难题，武汉大学人民医院的研究人员开展 HMGCL 在骨肉瘤中作用的研究。结果发现 HMGCL 可抑制骨肉瘤进展，或为新治疗靶点。推荐科研读者阅读，助于了解骨肉瘤治疗新方向，开拓研究思路。

Celcuity's gedatolisib, a dual PI3K/mTOR inhibitor, shows promise in Phase 3 breast cancer trials. Click here to read an ...

We have shown that tumors with HER2 amplification or PI3K mutation are selectively dependent for growth on the PI3K pathway and are sensitive to specific inhibitors of PI3K or AKT. Inhibition of PI3K ...

The mechanistic (or mammalian) target of rapamycin (mTOR) signaling pathway ... anti-depressive effect was produced through the PI3K and mTOR pathway. The IL-PFC in rodents is considered ...